| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |